cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.6084704
title: Additional file 3 of A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer

description: Unguided principal component analysis to identify batch effect in the TCGA data set as a function of genes from chemoradioresistance-associated pathways. p=0.118, indicating absence of significant batch effect in the data. Samples in each batch are denoted by a different colour and symbol. (TXT 2.05 kb)
DOI: 10.6084/m9.figshare.6084704.v1
title: Additional file 3 of A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer

description: Unguided principal component analysis to identify batch effect in the TCGA data set as a function of genes from chemoradioresistance-associated pathways. p=0.118, indicating absence of significant batch effect in the data. Samples in each batch are denoted by a different colour and symbol. (TXT 2.05 kb)
DOI: 10.6084/m9.figshare.6084701
title: MOESM5 of Control charts for monitoring mood stability as a predictor of severe episodes in patients with bipolar disorder

description: Additional file 5. Sensitivity and PPV of run sum procedure for predicting manic episodes within the next four weeks.
DOI: 10.6084/m9.figshare.6084701.v1
title: MOESM5 of Control charts for monitoring mood stability as a predictor of severe episodes in patients with bipolar disorder

description: Additional file 5. Sensitivity and PPV of run sum procedure for predicting manic episodes within the next four weeks.
DOI: 10.6084/m9.figshare.6084695
title: Additional file 7: of Negative and positive control ranges in the bacterial reverse mutation test: JEMS/BMS collaborative study

description: Figure S6. Individual dose-response curves showing the positive control articles in the presence of S9 mix were generated from data obtained by each participating laboratory (each laboratory is indicated by a different color). The doses (in Îźg/plate) for each positive control article are the same as those shown in Figs. 6, 7, 8, 9, and 10. S9 fraction was purchased from Kikkoman or Oriental Yeast, and while some laboratories used that same lots, other laboratories used different lots from the same manufacturers. Laboratory identification numbers are indicated on the right-hand side of each figure. (ODP 516Â kb)
DOI: 10.6084/m9.figshare.6084695.v1
title: Additional file 7: of Negative and positive control ranges in the bacterial reverse mutation test: JEMS/BMS collaborative study

description: Figure S6. Individual dose-response curves showing the positive control articles in the presence of S9 mix were generated from data obtained by each participating laboratory (each laboratory is indicated by a different color). The doses (in Îźg/plate) for each positive control article are the same as those shown in Figs. 6, 7, 8, 9, and 10. S9 fraction was purchased from Kikkoman or Oriental Yeast, and while some laboratories used that same lots, other laboratories used different lots from the same manufacturers. Laboratory identification numbers are indicated on the right-hand side of each figure. (ODP 516Â kb)
DOI: 10.6084/m9.figshare.6084683
title: MOESM4 of Control charts for monitoring mood stability as a predictor of severe episodes in patients with bipolar disorder

description: Additional file 4. Sensitivity and PPV of individual Shewhartâ s control rules for predicting depressive episodes within the next four weeks using individual-moving range charts.
DOI: 10.6084/m9.figshare.6084683.v1
title: MOESM4 of Control charts for monitoring mood stability as a predictor of severe episodes in patients with bipolar disorder

description: Additional file 4. Sensitivity and PPV of individual Shewhartâ s control rules for predicting depressive episodes within the next four weeks using individual-moving range charts.
DOI: 10.6084/m9.figshare.6084680
title: Additional file 1: of A method for determining haploid and triploid genotypes and their association with vascular phenotypes in Williams syndrome and 7q11.23 duplication syndrome

description: R script used for analyses. This file contains R code used to identify CNV genotypes and to perform association analyses with haploid genotypes. (R 4Â kb)
DOI: 10.6084/m9.figshare.6084680.v1
title: Additional file 1: of A method for determining haploid and triploid genotypes and their association with vascular phenotypes in Williams syndrome and 7q11.23 duplication syndrome

description: R script used for analyses. This file contains R code used to identify CNV genotypes and to perform association analyses with haploid genotypes. (R 4Â kb)
DOI: 10.6084/m9.figshare.6084677
title: Additional file 6: of Negative and positive control ranges in the bacterial reverse mutation test: JEMS/BMS collaborative study

description: Figure S5. Dose-response curves of revertant Escherichia coli strain WP2uvrA colonies following treatment with AF-2 in the absence of S9 mix (a), or with 2AA in the presence of S9 mix (b). Individual dose-response curves were generated using results produced by each participating laboratory in 2016 (different colors indicate different laboratories). The doses tested were 0.0025, 0.005, and 0.01 μg/plate for AF-2, and 2.5, 5.0, and 10 μg/plate for 2AA. (ODP 342 kb)
DOI: 10.6084/m9.figshare.6084677.v1
title: Additional file 6: of Negative and positive control ranges in the bacterial reverse mutation test: JEMS/BMS collaborative study

description: Figure S5. Dose-response curves of revertant Escherichia coli strain WP2uvrA colonies following treatment with AF-2 in the absence of S9 mix (a), or with 2AA in the presence of S9 mix (b). Individual dose-response curves were generated using results produced by each participating laboratory in 2016 (different colors indicate different laboratories). The doses tested were 0.0025, 0.005, and 0.01 μg/plate for AF-2, and 2.5, 5.0, and 10 μg/plate for 2AA. (ODP 342 kb)
DOI: 10.6084/m9.figshare.6084671
title: Additional file 1 of A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer

description: Workflow of the modified SVM-RFE used for selecting a set of genes that discriminated between rapidly-progressing and slow-progressing GBM patients. (XLSX 66.7 kb)
DOI: 10.6084/m9.figshare.6084671.v1
title: Additional file 1 of A 35-gene signature discriminates between rapidly- and slowly-progressing glioblastoma multiforme and predicts survival in known subtypes of the cancer

description: Workflow of the modified SVM-RFE used for selecting a set of genes that discriminated between rapidly-progressing and slow-progressing GBM patients. (XLSX 66.7 kb)
DOI: 10.6084/m9.figshare.6084662
title: MOESM3 of Control charts for monitoring mood stability as a predictor of severe episodes in patients with bipolar disorder

description: Additional file 3. Sensitivity and PPV of individual Shewhartâ s control rules for predicting manic episodes within the next four weeks using individual-moving range charts.
DOI: 10.6084/m9.figshare.6084662.v1
title: MOESM3 of Control charts for monitoring mood stability as a predictor of severe episodes in patients with bipolar disorder

description: Additional file 3. Sensitivity and PPV of individual Shewhartâ s control rules for predicting manic episodes within the next four weeks using individual-moving range charts.
DOI: 10.6084/m9.figshare.6084659
title: Additional file 5: of Negative and positive control ranges in the bacterial reverse mutation test: JEMS/BMS collaborative study

description: Figure S4. Dose-response curves of revertant Salmonella Typhimurium strain TA1537 colonies following treatment with 9AA in the absence of S9 mix (a), or with 2AA in the presence of S9 mix (b). Individual dose-response curves were generated using results produced by each participating laboratory in 2016 (different colors indicate different laboratories). The doses tested were 20, 40, and 80 μg/plate for 9AA, and 0.5, 1.0, and 2.0 μg/plate for 2AA. (ODP 343 kb)
DOI: 10.6084/m9.figshare.6084659.v1
title: Additional file 5: of Negative and positive control ranges in the bacterial reverse mutation test: JEMS/BMS collaborative study

description: Figure S4. Dose-response curves of revertant Salmonella Typhimurium strain TA1537 colonies following treatment with 9AA in the absence of S9 mix (a), or with 2AA in the presence of S9 mix (b). Individual dose-response curves were generated using results produced by each participating laboratory in 2016 (different colors indicate different laboratories). The doses tested were 20, 40, and 80 μg/plate for 9AA, and 0.5, 1.0, and 2.0 μg/plate for 2AA. (ODP 343 kb)
DOI: 10.6084/m9.figshare.6084644
title: MOESM2 of Control charts for monitoring mood stability as a predictor of severe episodes in patients with bipolar disorder

description: Additional file 2. Sensitivity and PPV of individual Shewhartâ s control rules for predicting depressive episodes within the next four weeks using universal and personalized X-bar charts.
DOI: 10.6084/m9.figshare.6084644.v1
title: MOESM2 of Control charts for monitoring mood stability as a predictor of severe episodes in patients with bipolar disorder

description: Additional file 2. Sensitivity and PPV of individual Shewhartâ s control rules for predicting depressive episodes within the next four weeks using universal and personalized X-bar charts.
DOI: 10.6084/m9.figshare.6084638
title: Additional file 4: of Negative and positive control ranges in the bacterial reverse mutation test: JEMS/BMS collaborative study

description: Figure S3. Dose-response curves of revertant Salmonella Typhimurium strain TA1535 colonies following treatment with SA in the absence of S9 mix (a), or with 2AA in the presence of S9 mix (b). Individual dose-response curves were generated using results produced by each participating laboratory in 2016 (different colors indicate different laboratories). The doses tested were 0.125, 0.25, and 0.5 μg/plate for SA, and 0.5, 1.0, and 2.0 μg/plate for 2AA. (ODP 411 kb)
DOI: 10.6084/m9.figshare.6084638.v1
title: Additional file 4: of Negative and positive control ranges in the bacterial reverse mutation test: JEMS/BMS collaborative study

description: Figure S3. Dose-response curves of revertant Salmonella Typhimurium strain TA1535 colonies following treatment with SA in the absence of S9 mix (a), or with 2AA in the presence of S9 mix (b). Individual dose-response curves were generated using results produced by each participating laboratory in 2016 (different colors indicate different laboratories). The doses tested were 0.125, 0.25, and 0.5 μg/plate for SA, and 0.5, 1.0, and 2.0 μg/plate for 2AA. (ODP 411 kb)
DOI: 10.6084/m9.figshare.6084626
title: Additional file 3: of Negative and positive control ranges in the bacterial reverse mutation test: JEMS/BMS collaborative study

description: Figure S2. Dose-response curves of revertant Salmonella Typhimurium strain TA98 colonies following treatment with AF-2 in the absence of S9 mix (a), or treatment with 2AA in the presence of S9 mix (b). Individual dose-response curves were generated using results produced by each participating laboratory in 2016 (different colors indicate different laboratories). The doses tested were 0.025, 0.05, and 0.1 μg/plate for AF-2, and 0.125, 0.25, and 0.5 μg/plate for 2AA. (ODP 434 kb)
DOI: 10.6084/m9.figshare.6084626.v1
title: Additional file 3: of Negative and positive control ranges in the bacterial reverse mutation test: JEMS/BMS collaborative study

description: Figure S2. Dose-response curves of revertant Salmonella Typhimurium strain TA98 colonies following treatment with AF-2 in the absence of S9 mix (a), or treatment with 2AA in the presence of S9 mix (b). Individual dose-response curves were generated using results produced by each participating laboratory in 2016 (different colors indicate different laboratories). The doses tested were 0.025, 0.05, and 0.1 μg/plate for AF-2, and 0.125, 0.25, and 0.5 μg/plate for 2AA. (ODP 434 kb)
DOI: 10.6084/m9.figshare.6084611
title: MOESM1 of Control charts for monitoring mood stability as a predictor of severe episodes in patients with bipolar disorder

description: Additional file 1. Sensitivity and PPV of individual Shewhartâ s control rules for predicting manic episodes within the next four weeks using universal and personalized X-bar charts.
DOI: 10.6084/m9.figshare.6084611.v1
title: MOESM1 of Control charts for monitoring mood stability as a predictor of severe episodes in patients with bipolar disorder

description: Additional file 1. Sensitivity and PPV of individual Shewhartâ s control rules for predicting manic episodes within the next four weeks using universal and personalized X-bar charts.
DOI: 10.6084/m9.figshare.6084599
title: Additional file 2: of Negative and positive control ranges in the bacterial reverse mutation test: JEMS/BMS collaborative study

description: Figure S1. Dose-response curves of revertant Salmonella Typhimurium strain TA100 colonies following treatment with AF-2 in the absence of S9 mix (a), or with 2AA in the presence of S9 mix (b). Individual dose-response curves were generated using results produced by each participating laboratory in 2016 (different colors indicate different laboratories). The doses tested were 0.0025, 0.005, and 0.01 μg/plate for AF-2, and 0.25, 0.5, and 1.0 μg/plate for 2AA. (ODP 423 kb)
DOI: 10.6084/m9.figshare.6084599.v1
title: Additional file 2: of Negative and positive control ranges in the bacterial reverse mutation test: JEMS/BMS collaborative study

description: Figure S1. Dose-response curves of revertant Salmonella Typhimurium strain TA100 colonies following treatment with AF-2 in the absence of S9 mix (a), or with 2AA in the presence of S9 mix (b). Individual dose-response curves were generated using results produced by each participating laboratory in 2016 (different colors indicate different laboratories). The doses tested were 0.0025, 0.005, and 0.01 μg/plate for AF-2, and 0.25, 0.5, and 1.0 μg/plate for 2AA. (ODP 423 kb)
DOI: 10.6084/m9.figshare.6084584
title: Additional file 1: of The constitutive differential transcriptome of a brain circuit for vocal learning

description: Table S1. Summary of the numbers of oligos and cDNAs analyzed for each nucleus. Table S2. Summary of the subsets of differential vs. non-differential genes analyzed for each nucleus to establish the p-value cutoffs in Fig. 2. Table S3. List of genes that are differentially regulated in HVC vs. Shelf. Table S4. List of genes that are differentially regulated in RA vs. VLA. Table S5. List of genes that are differentially regulated in nXIIts vs. SSP. Table S6. List of genes that are differentially regulated in Area X vs. VSP. Table S7. Pathways significantly over-represented in HVC. Table S8. Pathways significantly over-represented in RA. Table S9. Pathways significantly over-represented in nXIIts. Table S10. Pathways significantly over-represented in Area X. Table S11. Level 5 Gene Ontology (GO) terms significantly over-represented in HVC. Table S12. Level 5 Gene Ontology (GO) terms significantly over-represented in RA. Table S13. Level 5 Gene Ontology (GO) terms significantly over-represented in nXIIts. Table S14. Level 5 Gene Ontology (GO) terms significantly over-represented in Area X. Table S15. Unique and shared markers of song system nuclei. Table S16. Summary of in situ and array data analyzed to assess gene regulation in Figs. 4-9. (XLSX 244Â kb)
DOI: 10.6084/m9.figshare.6084584.v1
title: Additional file 1: of The constitutive differential transcriptome of a brain circuit for vocal learning

description: Table S1. Summary of the numbers of oligos and cDNAs analyzed for each nucleus. Table S2. Summary of the subsets of differential vs. non-differential genes analyzed for each nucleus to establish the p-value cutoffs in Fig. 2. Table S3. List of genes that are differentially regulated in HVC vs. Shelf. Table S4. List of genes that are differentially regulated in RA vs. VLA. Table S5. List of genes that are differentially regulated in nXIIts vs. SSP. Table S6. List of genes that are differentially regulated in Area X vs. VSP. Table S7. Pathways significantly over-represented in HVC. Table S8. Pathways significantly over-represented in RA. Table S9. Pathways significantly over-represented in nXIIts. Table S10. Pathways significantly over-represented in Area X. Table S11. Level 5 Gene Ontology (GO) terms significantly over-represented in HVC. Table S12. Level 5 Gene Ontology (GO) terms significantly over-represented in RA. Table S13. Level 5 Gene Ontology (GO) terms significantly over-represented in nXIIts. Table S14. Level 5 Gene Ontology (GO) terms significantly over-represented in Area X. Table S15. Unique and shared markers of song system nuclei. Table S16. Summary of in situ and array data analyzed to assess gene regulation in Figs. 4-9. (XLSX 244Â kb)
DOI: 10.6084/m9.figshare.6084566
title: Additional file 6: of Lipid accumulation in human breast cancer cells injured by iron depletors

description: Up-regulated in Dp44mT-treated cells versus untreated. Differential expression was considered as significant if (1) a protein was present only in untreated or treated cells or (2) its normalised (according to the LFQ algorithm) intensity resulted in a statistical difference, as calculated by the welchâ s t-test (t-test cut-off at p value = 0.0167). These data have been deposited to the ProteomeXchange Consortium ( http://proteomecentral.proteomexchange.org/cgi/GetDataset ) via the PRIDE (VizcaĂ­no et al., 2016 PubMed ID: 26527722) partner repository with the dataset identifier PXD007595. (XLS 537 kb)
DOI: 10.6084/m9.figshare.6084566.v1
title: Additional file 6: of Lipid accumulation in human breast cancer cells injured by iron depletors

description: Up-regulated in Dp44mT-treated cells versus untreated. Differential expression was considered as significant if (1) a protein was present only in untreated or treated cells or (2) its normalised (according to the LFQ algorithm) intensity resulted in a statistical difference, as calculated by the welchâ s t-test (t-test cut-off at p value = 0.0167). These data have been deposited to the ProteomeXchange Consortium ( http://proteomecentral.proteomexchange.org/cgi/GetDataset ) via the PRIDE (VizcaĂ­no et al., 2016 PubMed ID: 26527722) partner repository with the dataset identifier PXD007595. (XLS 537 kb)
DOI: 10.6084/m9.figshare.6084545
title: Additional file 5: of Lipid accumulation in human breast cancer cells injured by iron depletors

description: Down-regulated in Dp44mT-treated cells versus untreated. (XLS 721 kb)
DOI: 10.6084/m9.figshare.6084545.v1
title: Additional file 5: of Lipid accumulation in human breast cancer cells injured by iron depletors

description: Down-regulated in Dp44mT-treated cells versus untreated. (XLS 721 kb)
DOI: 10.6084/m9.figshare.6084524
title: Additional file 4: of Lipid accumulation in human breast cancer cells injured by iron depletors

description: Up-regulated in DFO-treated cells versus untreated. (XLS 375 kb)
DOI: 10.6084/m9.figshare.6084524.v1
title: Additional file 4: of Lipid accumulation in human breast cancer cells injured by iron depletors

description: Up-regulated in DFO-treated cells versus untreated. (XLS 375 kb)
DOI: 10.6084/m9.figshare.6084506
title: Additional files 3: of Lipid accumulation in human breast cancer cells injured by iron depletors

description: ReportsÂ ofÂ statistical results, specifically up- and down- regulated proteins in DFO- or Dp44mT-treated cells with respect to control. Down-regulated in DFO- treated cells versus untreated. (XLS 618 kb)
DOI: 10.6084/m9.figshare.6084506.v1
title: Additional files 3: of Lipid accumulation in human breast cancer cells injured by iron depletors

description: ReportsÂ ofÂ statistical results, specifically up- and down- regulated proteins in DFO- or Dp44mT-treated cells with respect to control. Down-regulated in DFO- treated cells versus untreated. (XLS 618 kb)
DOI: 10.6084/m9.figshare.6084455
title: Additional file 1: of Annual Dialysis Data Report 2015, JSDT Renal Data Registry

description: Table S1. Cumulative survival rates by incident year, 1983â 2014. (XLSX 20 kb)
DOI: 10.6084/m9.figshare.6084455.v1
title: Additional file 1: of Annual Dialysis Data Report 2015, JSDT Renal Data Registry

description: Table S1. Cumulative survival rates by incident year, 1983â 2014. (XLSX 20 kb)
DOI: 10.6084/m9.figshare.6084329
title: Additional file 2: of Genetic insights into dispersal distance and disperser fitness of African lions (Panthera leo) from the latitudinal extremes of the Kruger National Park, South Africa

description: Comma delimited sheet (*.csv) with raw data per individual, including data on microsatellite genotype, mtDNA haplotype number, sampling date, GPS coordinates, age, sex, BCS, FIV status, BTB status, socialisation, territory size, cluster assignment according to Structure. (CSV 29 kb)
DOI: 10.6084/m9.figshare.6084329.v1
title: Additional file 2: of Genetic insights into dispersal distance and disperser fitness of African lions (Panthera leo) from the latitudinal extremes of the Kruger National Park, South Africa

description: Comma delimited sheet (*.csv) with raw data per individual, including data on microsatellite genotype, mtDNA haplotype number, sampling date, GPS coordinates, age, sex, BCS, FIV status, BTB status, socialisation, territory size, cluster assignment according to Structure. (CSV 29 kb)
DOI: 10.6084/m9.figshare.6084263
title: Additional file 3: of KARS-related diseases: progressive leukoencephalopathy with brainstem and spinal cord calcifications as new phenotype and a review of literature

description: Information about the identified KARS mutations. (XLSX 8Â kb)
DOI: 10.6084/m9.figshare.6084263.v1
title: Additional file 3: of KARS-related diseases: progressive leukoencephalopathy with brainstem and spinal cord calcifications as new phenotype and a review of literature

description: Information about the identified KARS mutations. (XLSX 8Â kb)
DOI: 10.6084/m9.figshare.6084230
title: Additional file 2: of KARS-related diseases: progressive leukoencephalopathy with brainstem and spinal cord calcifications as new phenotype and a review of literature

description: List of the candidate variants identified by WES in Patient A. (XLSX 10Â kb)
DOI: 10.6084/m9.figshare.6084230.v1
title: Additional file 2: of KARS-related diseases: progressive leukoencephalopathy with brainstem and spinal cord calcifications as new phenotype and a review of literature

description: List of the candidate variants identified by WES in Patient A. (XLSX 10Â kb)
DOI: 10.6084/m9.figshare.6084215
title: Additional file 1: of KARS-related diseases: progressive leukoencephalopathy with brainstem and spinal cord calcifications as new phenotype and a review of literature

description: List of the genes present in the custom panels. (XLSX 12Â kb)
DOI: 10.6084/m9.figshare.6084215.v1
title: Additional file 1: of KARS-related diseases: progressive leukoencephalopathy with brainstem and spinal cord calcifications as new phenotype and a review of literature

description: List of the genes present in the custom panels. (XLSX 12Â kb)
DOI: 10.6084/m9.figshare.6084200
title: Additional file 1: of Using differential item functioning to evaluate potential bias in a high stakes postgraduate knowledge based assessment

description: High resolution images of the plots contained in the paper. (ZIP 2058 kb)
DOI: 10.6084/m9.figshare.6084200.v1
title: Additional file 1: of Using differential item functioning to evaluate potential bias in a high stakes postgraduate knowledge based assessment

description: High resolution images of the plots contained in the paper. (ZIP 2058 kb)